{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:42:55Z","timestamp":1780497775305,"version":"3.54.1"},"reference-count":84,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jfma.2024.11.001","type":"journal-article","created":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T06:51:59Z","timestamp":1730616719000},"page":"902-911","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cutaneous T-cell lymphoma: Consensus on diagnosis and management in Taiwan"],"prefix":"10.1016","volume":"124","author":[{"given":"Tai-Chung","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Hsing","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4410-3821","authenticated-orcid":false,"given":"Pa-Fan","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4365-4533","authenticated-orcid":false,"given":"Chao-Kai","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Yio","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Shan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Peng","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsen-Fang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.jfma.2024.11.001_bib1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jfma.2024.11.001_bib2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.det.2022.07.019","article-title":"A practical guide to the diagnosis, evaluation, and treatment of cutaneous T-cell lymphoma","volume":"41","author":"Shimshak","year":"2023","journal-title":"Dermatol Clin"},{"issue":"5","key":"10.1016\/j.jfma.2024.11.001_bib3","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/kjm2.12659","article-title":"Distribution and clinical features of lymphomas involving skin in Taiwan","volume":"39","author":"Wu","year":"2023","journal-title":"Kaohsiung J Med Sci"},{"issue":"7","key":"10.1016\/j.jfma.2024.11.001_bib4","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.pathol.2018.08.008","article-title":"Mycosis fungoides in Taiwan shows a relatively high frequency of large cell transformation and CD56 expression","volume":"50","author":"Wang","year":"2018","journal-title":"Pathology"},{"issue":"10","key":"10.1016\/j.jfma.2024.11.001_bib5","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jamadermatol.2023.2634","article-title":"Prognostic factors and survival outcomes among patients with mycosis fungoides in China: a 12-year review","volume":"159","author":"Chen","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"8","key":"10.1016\/j.jfma.2024.11.001_bib6","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1111\/jdv.15526","article-title":"Epidemiology and prognostic factors for mycosis fungoides and S\u00e9zary syndrome in a multi-ethnic Asian cohort: a 12-year review","volume":"33","author":"Lim","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.jfma.2024.11.001_bib7","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/jdv.16160","article-title":"Risk of mycosis fungoides in psoriatic patients: a critical review","volume":"34","author":"Biondo","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jfma.2024.11.001_bib8","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jaad.2022.12.001","article-title":"Diagnosis of mycosis fungoides or S\u00e9zary syndrome after dupilumab use: a systematic review","volume":"88","author":"Jfri","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jfma.2024.11.001_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2021.100148","article-title":"Understanding the enigmatic association between mycosis fungoides and psoriasis: report of two cases and review of the literature","volume":"12","author":"Diakomopoulos","year":"2021","journal-title":"Metabol Open"},{"issue":"6","key":"10.1016\/j.jfma.2024.11.001_bib10","doi-asserted-by":"crossref","first-page":"953","DOI":"10.5114\/ada.2021.107553","article-title":"Safety and danger of biologic treatments in psoriasis in context of cutaneous T-cell lymphoma (CTCL)","volume":"38","author":"Ko\u0142kowski","year":"2021","journal-title":"Postepy Dermatol Alergol"},{"issue":"6","key":"10.1016\/j.jfma.2024.11.001_bib11","first-page":"1713","volume":"110","author":"Olsen","year":"2007"},{"issue":"6","key":"10.1016\/j.jfma.2024.11.001_bib12","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jaad.2005.08.057","article-title":"Defining early mycosis fungoides","volume":"53","author":"Pimpinelli","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jfma.2024.11.001_bib13","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/bjd.17258","article-title":"The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients","volume":"181","author":"Scarisbrick","year":"2019","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jfma.2024.11.001_bib14","first-page":"93","article-title":"Mycosis fungoides: clinical and histologic features, staging, evaluation, and approach to treatment","volume":"43","author":"Abel","year":"1993","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.jfma.2024.11.001_bib15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archderm.135.1.26","article-title":"Clinical characteristics and long-term outcome of patients with generalized patch and\/or plaque (T2) mycosis fungoides","volume":"135","author":"Kim","year":"1999","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.jfma.2024.11.001_bib16","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood.2021012057","article-title":"Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC","volume":"140","author":"Olsen","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jfma.2024.11.001_bib17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jdin.2022.07.007","article-title":"Itch in patients with cutaneous T-cell lymphoma as a quality of life indicator","volume":"9","author":"Ottevanger","year":"2022","journal-title":"JAAD Int"},{"issue":"10","key":"10.1016\/j.jfma.2024.11.001_bib18","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/cncr.22252","article-title":"Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey","volume":"107","author":"Demierre","year":"2006","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.jfma.2024.11.001_bib19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1468-3083.2004.00937.x","article-title":"Clinicopathological spectrum of mycosis fungoides","volume":"18","author":"Kazakov","year":"2004","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jfma.2024.11.001_bib20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jdcr.2023.12.003","article-title":"Sezary syndrome initially presenting as pityriasis rubra pilaris: clinicopathologic study of 3 cases","volume":"44","author":"Alsawas","year":"2023","journal-title":"JAAD Case Rep"},{"issue":"S1","key":"10.1016\/j.jfma.2024.11.001_bib21","doi-asserted-by":"crossref","first-page":"66","DOI":"10.5045\/br.2023.2023023","article-title":"Mycosis fungoides and S\u00e9zary syndrome","volume":"58","author":"Lee","year":"2023","journal-title":"Blood Res"},{"issue":"10","key":"10.1016\/j.jfma.2024.11.001_bib22","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1001\/jama.1992.03480100060031","article-title":"Infections complicating mycosis fungoides and Sezary syndrome","volume":"267","author":"Axelrod","year":"1992","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jfma.2024.11.001_bib23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2133.2008.08612.x","article-title":"Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sezary syndrome","volume":"159","author":"Talpur","year":"2008","journal-title":"Br J Dermatol"},{"issue":"16","key":"10.1016\/j.jfma.2024.11.001_bib24","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1002\/cncr.28712","article-title":"Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project","volume":"120","author":"Carson","year":"2014","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.jfma.2024.11.001_bib25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/archderm.143.1.45","article-title":"Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts","volume":"143","author":"Huang","year":"2007","journal-title":"Arch Dermatol"},{"issue":"5 Pt 1","key":"10.1016\/j.jfma.2024.11.001_bib26","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0190-9622(09)80056-X","article-title":"Proceedings of the second international symposium on cutaneous T-cell lymphoma. Chicago, Illinois, oct. 13-17, 1993","volume":"31","author":"Herrmann","year":"1994","journal-title":"J Am Acad Dermatol"},{"issue":"27","key":"10.1016\/j.jfma.2024.11.001_bib27","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jfma.2024.11.001_bib28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4103\/ds.ds_15_21","article-title":"Juvenile folliculotropic mycosis fungoides mimicking tinea capitis: a case report and literature review","volume":"39","author":"Lu","year":"2021","journal-title":"Dermatol Sin"},{"key":"10.1016\/j.jfma.2024.11.001_bib29","doi-asserted-by":"crossref","DOI":"10.4103\/ds.DS-D-23-00207","article-title":"Granulomatous mycosis fungoides on the wrist of a middle-aged man","author":"Huang","year":"2024","journal-title":"Dermatol Sin"},{"issue":"3","key":"10.1016\/j.jfma.2024.11.001_bib30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/hon.2832","article-title":"Critical concepts and management recommendations for cutaneous T-cell lymphoma: a consensus-based position paper from the Italian Group of Cutaneous Lymphoma","volume":"39","author":"Zinzani","year":"2021","journal-title":"Hematol Oncol"},{"issue":"1","key":"10.1016\/j.jfma.2024.11.001_bib31","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ajh.26760","article-title":"Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Hristov","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jfma.2024.11.001_bib32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jdin.2021.01.002","article-title":"Topical treatments for early-stage mycosis fungoides using Grading Recommendations Assessment, Development and Evaluation (GRADE) criteria: a systematic review","volume":"3","author":"Wennberg","year":"2021","journal-title":"JAAD Int"},{"issue":"8","key":"10.1016\/j.jfma.2024.11.001_bib33","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archderm.134.8.949","article-title":"Topical corticosteroids for mycosis fungoides. Experience in 79 patients","volume":"134","author":"Zackheim","year":"1998","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.jfma.2024.11.001_bib34","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S0190-9622(89)70051-7","article-title":"Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma","volume":"20","author":"Vonderheid","year":"1989","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jfma.2024.11.001_bib35","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1396-0296.2003.01640.x","article-title":"Management with topical nitrogen mustard in mycosis fungoides","volume":"16","author":"Kim","year":"2003","journal-title":"Dermatol Ther"},{"issue":"9","key":"10.1016\/j.jfma.2024.11.001_bib36","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1001\/archderm.141.9.1117","article-title":"Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study","volume":"141","author":"de","year":"2005","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.jfma.2024.11.001_bib37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/2013.jamadermatol.541","article-title":"Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides","volume":"149","author":"Lessin","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.jfma.2024.11.001_bib38","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40257-021-00591-x","article-title":"The PROVe Study: US real-world experience with chlormethine\/mechlorethamine gel in combination with other therapies for patients with mycosis fungoides cutaneous T-cell lymphoma","volume":"22","author":"Kim","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jfma.2024.11.001_bib39","unstructured":"Valvhlor (mechlorethamine hydrochloride 0.016% topical gel. Drugs@FDA: FDA-Approved drugs. Available from:: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/202317s010lbl.pdf. Accessed March 2024."},{"issue":"3","key":"10.1016\/j.jfma.2024.11.001_bib40","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/archderm.138.3.325","article-title":"Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma","volume":"138","author":"Breneman","year":"2002","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.jfma.2024.11.001_bib41","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0190-9622(03)01475-0","article-title":"Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial","volume":"49","author":"Heald","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jfma.2024.11.001_bib42","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jaad.2003.09.005","article-title":"Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study","volume":"50","author":"Apisarnthanarax","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jfma.2024.11.001_bib43","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/1203475415626686","article-title":"Tazarotene 0.1% cream as monotherapy for early-stage cutaneous T-cell lymphoma","volume":"20","author":"Besner Morin","year":"2016","journal-title":"J Cutan Med Surg"},{"issue":"1","key":"10.1016\/j.jfma.2024.11.001_bib44","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4103\/0019-5154.174085","article-title":"New treatment options for mycosis fungoides","volume":"61","author":"Shipman","year":"2016","journal-title":"Indian J Dermatol"},{"issue":"12","key":"10.1016\/j.jfma.2024.11.001_bib45","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood-2015-02-630335","article-title":"Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma","volume":"126","author":"Rook","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jfma.2024.11.001_bib46","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jdin.2022.01.010","article-title":"Local skin reactions and the onset of influenza-like signs and symptoms induced by imiquimod","volume":"7","author":"Bhatia","year":"2022","journal-title":"JAAD Int"},{"issue":"6","key":"10.1016\/j.jfma.2024.11.001_bib47","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/ced.15162","article-title":"Usage and safety of topical tacrolimus in patients with mycosis fungoides","volume":"47","author":"Weiner","year":"2022","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"10.1016\/j.jfma.2024.11.001_bib48","doi-asserted-by":"crossref","first-page":"e425","DOI":"10.1016\/S2352-3026(22)00107-7","article-title":"Activity and safety of topical pimecrolimus in patients with early stage mycosis fungoides (PimTo-MF): a single-arm, multicentre, phase 2 trial","volume":"9","author":"Ortiz-Romero","year":"2022","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.jfma.2024.11.001_bib49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2015.09.033","article-title":"Guidelines for phototherapy of mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the United States Cutaneous Lymphoma Consortium","volume":"74","author":"Olsen","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jfma.2024.11.001_bib50","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/bjd.14317","article-title":"British Association of Dermatologists and British Photodermatology Group guidelines for the safe and effective use of psoralen-ultraviolet A therapy 2015","volume":"174","author":"Ling","year":"2016","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jfma.2024.11.001_bib51","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1111\/jdv.16283","article-title":"Impact of narrow-band ultraviolet B phototherapy on remission and relapses of mycosis fungoides in patients with Fitzpatrick skin III-IV","volume":"34","author":"Huang","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"10.1016\/j.jfma.2024.11.001_bib52","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1001\/archderm.1992.01680170063007","article-title":"Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma","volume":"128","author":"Ramsay","year":"1992","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.jfma.2024.11.001_bib53","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2015.09.033","article-title":"Guidelines for phototherapy of mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the United States Cutaneous Lymphoma Consortium","volume":"74","author":"Olsen","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jfma.2024.11.001_bib54","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/ds.ds_14_18","article-title":"Analysis of the treatment results of localized conventional radiotherapy for early- and advanced-stage cutaneous T-cell lymphoma refractory to other skin-directed therapies","volume":"37","author":"Park","year":"2019","journal-title":"Dermatol Sin"},{"key":"10.1016\/j.jfma.2024.11.001_bib55","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Guidelines for Primary Cutaneous Lymphomas (Version 1.2023). Available from: https:\/\/www.nccn.org. Accessed May 2023."},{"issue":"1","key":"10.1016\/j.jfma.2024.11.001_bib56","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijrobp.2015.01.008","article-title":"Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"92","author":"Specht","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.jfma.2024.11.001_bib57","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.3390\/ijms24054492","article-title":"Total skin treatment with helical arc radiotherapy","volume":"24","author":"Nien","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jfma.2024.11.001_bib58","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/717589","article-title":"Helical irradiation of the total skin with dose painting to replace total skin electron beam therapy for therapy-refractory cutaneous CD4+ T-cell lymphoma","volume":"2013","author":"Hsieh","year":"2013","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.jfma.2024.11.001_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113343","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome - update 2023","volume":"195","author":"Latzka","year":"2023","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.jfma.2024.11.001_bib60","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/bjd.15355","article-title":"Recommendations for treatment in folliculotropic mycosis fungoides: report of the Dutch Cutaneous Lymphoma Group","volume":"177","author":"van Santen","year":"2017","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.jfma.2024.11.001_bib61","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2340\/00015555-3013","article-title":"Treatment of early folliculotropic mycosis fungoides with special focus on psoralen plus ultraviolet A","volume":"98","author":"Amitay-Laish","year":"2018","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"10.1016\/j.jfma.2024.11.001_bib62","doi-asserted-by":"crossref","first-page":"192","DOI":"10.4103\/1027-8117.354328","article-title":"Folliculotropic mycosis fungoides successfully treated with bath psoralen plus ultraviolet a therapy","volume":"40","author":"Hung","year":"2022","journal-title":"Dermatol Sin"},{"issue":"6","key":"10.1016\/j.jfma.2024.11.001_bib63","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s00280-012-1847-5","article-title":"Phase I study of chidamide (CS055\/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas","volume":"69","author":"Dong","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.jfma.2024.11.001_bib64","article-title":"Effective remission of chidamide on treatment of advanced mycosis fungoides: an unusual case report","volume":"32","author":"Che","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jfma.2024.11.001_bib65","article-title":"Case report: outcome and adverse events of anti-PD-1 antibody plus chidamide for relapsed\/refractory S\u00e9zary syndrome: case series and a literature review","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.jfma.2024.11.001_bib66","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jamadermatol.2020.4901","article-title":"Brentuximab vedotin for relapsed or refractory S\u00e9zary syndrome","volume":"157","author":"Lewis","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"32","key":"10.1016\/j.jfma.2024.11.001_bib67","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.2014.60.3969","article-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and S\u00e9zary syndrome with variable CD30 expression level: a multi-institution collaborative project","volume":"33","author":"Kim","year":"2015","journal-title":"J Clin Oncol"},{"issue":"10094","key":"10.1016\/j.jfma.2024.11.001_bib68","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.jfma.2024.11.001_bib69","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1182\/bloodadvances.2021004710","article-title":"Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data","volume":"5","author":"Horwitz","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jfma.2024.11.001_bib70","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ejca.2021.01.054","article-title":"Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: an ALCANZA sub-analysis","volume":"148","author":"Kim","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jfma.2024.11.001_bib71","unstructured":"Laws & Regulations Database of The Republic of China (Taiwan). Regulations related to national insurance coverage for medications. Available from:: https:\/\/law.moj.gov.tw\/LawClass\/LawSingle.aspx?pcode=L0060035&flno=83. Last accessed on May, 2024."},{"issue":"1","key":"10.1016\/j.jfma.2024.11.001_bib72","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in relapsed and refractory mycosis fungoides and S\u00e9zary syndrome: a multicenter phase II study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfma.2024.11.001_bib73","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/1360740","article-title":"Suggested guidelines for the treatment of mycosis fungoides in countries with limited resources","volume":"2023","author":"Ibrahim","year":"2023","journal-title":"Dermatol Res Pract"},{"issue":"8","key":"10.1016\/j.jfma.2024.11.001_bib74","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.bbmt.2009.04.017","article-title":"A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and S\u00e9zary syndrome","volume":"15","author":"Wu","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jfma.2024.11.001_bib75","series-title":"The EBMT handbook : hematopoietic cell transplantation and cellular therapies","year":"2024"},{"issue":"1","key":"10.1016\/j.jfma.2024.11.001_bib76","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4103\/ds.ds_5_22","article-title":"Anaplastic large-cell lymphoma presenting as large ulcerated tumors and small papules in a 15-year-old girl","volume":"40","author":"Matsuzawa","year":"2022","journal-title":"Dermatol Sin"},{"issue":"4","key":"10.1016\/j.jfma.2024.11.001_bib77","doi-asserted-by":"crossref","first-page":"212","DOI":"10.4103\/ds.ds_41_21","article-title":"Lymphomatoid papulosis with DUSP22-IRF4 rearrangement on 6p25-3: a case report","volume":"39","author":"Mao","year":"2021","journal-title":"Dermatol Sin"},{"issue":"12","key":"10.1016\/j.jfma.2024.11.001_bib78","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1182\/blood.V95.12.3653","article-title":"Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment","volume":"95","author":"Bekkenk","year":"2000","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jfma.2024.11.001_bib79","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/ced.13256","article-title":"First-line treatment in lymphomatoid papulosis: a retrospective multicentre study","volume":"43","author":"Fern\u00e1ndez-de-Misa","year":"2018","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"10.1016\/j.jfma.2024.11.001_bib80","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jaad.2008.12.043","article-title":"Wet dressings used with topical corticosteroids for pruritic dermatoses: a retrospective study","volume":"60","author":"Bingham","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jfma.2024.11.001_bib81","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2340\/00015555-0789","article-title":"Pruritus in cutaneous T-cell lymphomas: frequent, often severe and difficult to treat","volume":"90","author":"Meyer","year":"2010","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"10.1016\/j.jfma.2024.11.001_bib82","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1111\/bjd.16128","article-title":"Aprepitant improves refractory pruritus in primary cutaneous T-cell lymphomas: experience of the Spanish Working Group on Cutaneous Lymphomas","volume":"178","author":"Maronas-Jimenez","year":"2018","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jfma.2024.11.001_bib83","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jaad.2006.04.025","article-title":"Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma","volume":"55","author":"Demierre","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jfma.2024.11.001_bib84","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1529-8019.2005.00032.x","article-title":"Ultraviolet phototherapy for pruritus","volume":"18","author":"Rivard","year":"2005","journal-title":"Dermatol Ther"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664624005175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664624005175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T04:33:40Z","timestamp":1758947620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664624005175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":84,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0929664624005175"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2024.11.001","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous T-cell lymphoma: Consensus on diagnosis and management in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2024.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}